You are here

  • Home
  • Archive
  • Volume 66, Issue 3
  • Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis

Alerts

Article menu

This article has Replies. Please see:

Download PDFPDF

PostScript
Letter
Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address